Biotech M&A is back. Ipsen set to fork out up to $1.3B for rare disease specialist Clementia

Merger Monday is back in full swing. Along with Roche buying Spark Therapeutics $ONCE, Parisian biotech Ipsen (Euronext: $IPN) is beefing up its rare disease arsenal by acquiring Canada’s Clementia Pharmaceuticals $CMTA, less than two years after the Montreal-based drug developer’s $120 million IPO.